Rani Therapeutics Holdings (RANI) Treasury Shares (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Treasury Shares of $225313.0 for Q1 2026, down 65.49% year-over-year from $652869.0 in Q1 2025, and down 35.39% quarter-over-quarter from $348702.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Treasury Shares (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Treasury Shares history runs 7 years deep, the most recent figure standing at $225313.0 for Q1 2026.
- In Q1 2026, Treasury Shares fell 65.49% year-over-year to $225313.0; the TTM figure through Mar 2026 stood at $225313.0 (down 65.49% YoY), while the FY2025 annual figure was $348702.0, down 57.05% from the prior year.
- Treasury Shares for Q1 2026 stood at $225313.0, down from $348702.0 in the prior quarter.
- The five-year high for Treasury Shares was $970100.0 in Q2 2022, with the low at $3257.0 in Q4 2024.
- The 5-year median for Treasury Shares is $450694.0 (2025), against an average of $456335.2.
- The sharpest annual moves came in 2022 and 2025: Treasury Shares tumbled 99.65% in 2022, then soared 10606.23% in 2025.
- Rani Therapeutics Holdings' Treasury Shares stood at $665500.0 in 2022, then tumbled by 94.95% to $33586.0 in 2023, then sank by 90.3% to $3257.0 in 2024, then jumped by 10606.23% to $348702.0 in 2025, then sank by 35.39% to $225313.0 in 2026.
- Business Quant data shows RANI's Treasury Shares at $225313.0 in Q1 2026, $348702.0 in Q4 2025, and $416305.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 167.21 Mn |
| Jun 30, 2026 | 167.21 Mn |
| Mar 31, 2026 | 225,313.00 |
| Mar 31, 2026 | 225,313.00 |
| Dec 31, 2025 | 348,702.00 |
| Dec 31, 2025 | 348,702.00 |
| Sep 30, 2025 | 416,305.00 |
| Sep 30, 2025 | 416,305.00 |
| Jun 30, 2025 | 485,083.00 |
| Jun 30, 2025 | 485,083.00 |
| Mar 31, 2025 | 652,869.00 |
| Mar 31, 2025 | 652,869.00 |
| Dec 31, 2024 | 3,257.00 |
| Dec 31, 2024 | 3,257.00 |
| Sep 30, 2024 | 893,294.00 |
| Sep 30, 2024 | 893,294.00 |
| Dec 31, 2023 | 33,586.00 |
| Dec 31, 2023 | 33,586.00 |
| Dec 31, 2022 | 665,500.00 |
| Dec 31, 2022 | 665,500.00 |